Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
112 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
Rank Status Study
21 Recruiting Mesenteric Ischemia in the Emergency Department: a Retrospective Multicenter Study
Condition: Acute Mesenteric Ischemia
Intervention:
22 Recruiting Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis
Condition: Spontaneous Bacterial Peritonitis
Intervention: Other: serum amyloid A level
23 Not yet recruiting Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
Conditions: End-Stage Kidney Disease;   Peritonitis
Intervention: Other: PD Product Check List
24 Recruiting Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery
Condition: Peritonitis
Intervention: Other: No intervention, merely observational
25 Not yet recruiting Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Neoplasm;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Ruxolitinib Phosphate;   Procedure: Therapeutic Conventional Surgery
26 Not yet recruiting Intra-abdominal Pressure and Dynamic Preload Variables
Condition: Pneumoperitoneum
Intervention: Device: determination of dynamic preload variables
27 Recruiting Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Conditions: Small Cell Lung Carcinoma;   Carcinoma, Squamous Cell of Head and Neck;   Stomach Neoplasms;   Triple Negative Breast Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Esophagogastric Junction Neoplasms
Interventions: Drug: paclitaxel + carboplatin;   Drug: carboplatin + etoposide;   Drug: gemcitabine + carboplatin;   Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin;   Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);   Biological: durvalumab;   Biological: tremelimumab
28 Recruiting Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia
Condition: Mesenteric Ischemia
Intervention: Drug: Heparin injection
29 Recruiting Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Conditions: Portal Vein Thrombosis;   Mesenteric Vein Thrombosis;   Splenic Vein Thrombosis
Intervention: Drug: rivaroxaban
30 Recruiting Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
Conditions: Cirrhosis of the Liver;   Ascites;   Spontaneous Bacterial Peritonitis
Intervention: Other: Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
31 Recruiting Study of IMGN853 in Comb. With Bevacizumab, Carboplatin, PLD or Pembrolizumab in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer
Interventions: Drug: IMGN853;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Pembrolizumab
32 Not yet recruiting Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery
Conditions: Prostatic Neoplasms;   Urinary Bladder Neoplasms
Interventions: Procedure: low-pressure pneumoperitoneum;   Procedure: standard-pressure pneumoperitoneum
33 Recruiting Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
Conditions: Cervical Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vulvar Carcinoma;   Uterine Corpus Cancer;   Vulvar Carcinoma;   Peritoneal Neoplasms
Interventions: Other: Palliative Therapy;   Other: Palliative Therapy + idiographic
34 Recruiting Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer
Conditions: Platinum-resistant Ovarian Cancer;   Platinum-resistant Fallopian Cancer;   Platinum-resistant Peritoneal Cancer
Interventions: Biological: CRS-207;   Drug: epacadostat (INCB024360)
35 Recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Olaparib;   Drug: Tremelimumab
36 Not yet recruiting Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)
Condition: Spontaneous Bacterial Peritonitis
Interventions: Drug: Vivomixx®;   Drug: Placebo
37 Recruiting Pneumoperitoneum Management With SurgiQuest AirSeal at Low vs. Higher Pressure ( PRESSURE )
Condition: Shoulder Pain
Intervention: Device: SurgiQuest AIRSEAL® Insufflation System (AIS)
38 Recruiting Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Biological: Prolanta, a human prolactin receptor antagonist
39 Not yet recruiting Epigenetic Determinants of Peritoneal Fibrosis
Condition: Peritoneal Fibrosis
Intervention:
40 Recruiting Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: High Grade Serous Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Procedure: Production of Genetically-modified T cells;   Drug: Cyclophosphamide;   Device: IP Catheter Insertion;   Genetic: Infusion of 4H11-28z/fIL-12/EFGRt+ Genetically-modified T cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years